

106<sup>th</sup> IAMM EQAS Microbiology: Bacteriology/ Serology
Department of Clinical Microbiology, Christian Medical College, Vellore-632004, Tamil Nadu
Email: eqas@cmcvellore.ac.in Phone: 0416-2282588



NABL ACCREDITED ISO / IEC 17043:2010, PC-1033 / 27.12.2018

DECEMBER 2020

106th EQAS EVALUATION REPORT

MEMBER ID: M

M 0 0 5 8

Marks Obtained: 62.5/67(93%)

## DECEMBER 2020 / BACTERIOLOGY SMEARS:

Question: Carry out the appropriate staining procedure and document the relevant observation.

Provide the Impression or probable organism seen (AS ASKED)

Please refer the attached evaluation format/answer template for details on the criteria for evaluation.

PLEASE NOTE: The inaccuracies in the participant report resulting in deduction of marks has been underlined in the expected report.

Exercise Question Number		Expected Report	Evaluation		
SM1	Please carry out a Gram stain on the given fixed smear	Presence of host cells & debris (1mark): Few pus cells	0	0.5	1
	prepared from a CSF specimen of a 72-year-old gentleman presenting with high grade	Description of Organism/s (2marks): Many (0.5) Gram positive (0.5) lanceolate shaped diplococci (1)	1.5	2	2.5
	fever, headache and vomiting for one day.	Probable organism (1 mark): Streptococcus pneumoniae	3	(5)	4
SM2	Please carry out a Gram stain on the given fixed smear	Presence of host cells & debris (Imark): No pus cells	0	0.5	1
prepared from a THROAT specimen of a 6-year old child		Description of Organism/s (2 marks): Many (0.5) Gram positive (0.5) slender club bacilli arranged Chinese letter pattern (1) along with few	1.5	2	2.5
	presenting with a sore throat and fever and malaise for 2 days.	Gram positive bacilli in palisade arrangement.  Possible organism (1 mark): Corynebacterium spp 3	3	3.5	4

CU3: Isolated as the predominant organism from an EXUDATE specimen of a left lower limb ulcer from a 63-year-old diabetic woman. FINAL IDENTIFICATION: Proteus mirabilis

Microscopy (Gram stain + Motility)	lity)		0 0.5(L)
Salient culture and biochemical findings enabling final identification	findings enabling final	*	1 2 3 🕘
(Minimum 3 key characteristics)			

Meropenem	Ertapenem	Piperacillin- Tazobactam	Levofloxacin	Co-trimoxazole	Tepot.	Susceptibility
≥23	212	≥3.1	175	>16	Zone size (mm)	
≤1.0	≥0.5	≥16	≤0.5	52/38	MIC (µg/ml)	EXPECTED REPORT
Susceptible	Susceptible	Susceptible	Susceptible	Susceptible	Interpretation	KEPOKI A TIEST
					Correct	PARTICIPA
					Incorrect	PAKITCIPANI KEPUKI
-1010	-1010	-101@	O101-	-1010	10 marks	MAKK
mE/ ME/ VME	mE/ME/VME	mE/ ME/ VME	mE/ ME/ VME	mE/ ME/ VME	Error	TAKE OF ENKOR

## DECEMBER 2020 / SEROLOGY

Please refer the attached evaluation format/answer template for details on the criteria for evaluation.

SE3	SE2	SE1		
CRP	WIDAL* Correct	RA	Parameter	
Positive		Negative	Your Result	
50.28 mg/L	Correct	9.3 IU/mL	Your Value	
	STO Negative			
Positive	STO STH Interpretation	Negative	Intended Result	
		ve .	be	
Turbidimetry (n-330)	Slide agglutination	Turbidimetry (n-245)	Method	
60.0593		8.5538	Robust Mean	
60.0593 10.4966	Not Applicat	4.1086	Robust SD	
0.08 to	licable	0.0 to 31.260	Range (mg/L)	
-0.9		0.2	Z & Z's	
is.	×	2	Max Marks	
N	2	8	Your Score	

RA: Rheumatoid Factor, CRP: C-reactive Protein. NA: Not Applicable. \*Expected value is determined by the Proficiency Testing Provider (PTP).